Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
Trial Parameters
Brief Summary
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
Eligibility Criteria
Inclusion Criteria: All patients: * Adults (\>18 years) * Presenting with cutaneous psoriasis * Patients have signed an informed consent * Beneficiary of the health insurance, except for the AME Only for patients of Group 1 * Patients require systemic treatment for psoriasis * Patients are naïve to biological therapies Only for patients of Group 2: * Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision. * Patients are naïve to biological therapies or have received only one biologic, with a "wash-out" period of at least 4 months Non inclusion Criteria: For all : * Patient is minor * Patient is pregnant or breastfeeding * Patient is immunocompromised * Patient is under legal protection, curatorship, guardianship * Patient refuses consent * Patient is unable to comply with study requirements for geographic, social or psychiatric reason. * Beneficiary of the AME Only for patients of Group 1 * Patient has receive